Compare EPSN & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EPSN | ALXO |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 187.2M | 172.8M |
| IPO Year | 2018 | 2020 |
| Metric | EPSN | ALXO |
|---|---|---|
| Price | $5.16 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 56.9K | ★ 1.4M |
| Earning Date | 11-20-2026 | 11-20-2026 |
| Dividend Yield | ★ 4.84% | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | ★ 0.26 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.20 | $0.86 |
| 52 Week High | $6.65 | $2.66 |
| Indicator | EPSN | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 26.68 | 50.26 |
| Support Level | N/A | $1.03 |
| Resistance Level | $6.01 | $1.34 |
| Average True Range (ATR) | 0.24 | 0.14 |
| MACD | -0.14 | 0.03 |
| Stochastic Oscillator | 1.84 | 60.26 |
Epsilon Energy Ltd is a North American on-shore focused independent natural gas and oil company engaged in the acquisition, development, gathering and production of natural gas and oil reserves. Its properties include Appalachian Basin-Pennsylvania, Permian Basin-Texas and New Mexico, Anadarko Basin-Oklahoma, Powder River Basin-Wyoming, Western Canadian Sedimentary Basin-Alberta, Canada. Its segments include The Upstream segment activities include acquisition, development and production of natural gas and oil reserves on properties within the United States and Canada; and The Gas Gathering segment partners with two other companies to operate a natural gas gathering system. The Upstream segment derives the majority of the revenue.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.